Research location

Murcia

Spain

Published trials282

Site observations309

Linked trials published282

Page1 / 6

Research activity in Murcia

Spain

CureCurrent currently publishes aggregate city-level research activity for this location: 282 trials and 309 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Murcia

282 linked trials · page 1 of 6

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 · 2026-09-17 · 1 site observation

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With MelanomaNCT07476326 · 2026-09-09 · 1 site observation

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)NCT07864207 · 2026-07-28 · 1 site observation

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast CancerNCT07401381 · 2026-06-08 · 1 site observation

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized TrialNCT07015892 · 2026-03-01 · 1 site observation

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart FailureNCT07484009 · 2026-01-29 · 1 site observation

Effect of a Nutritional Product Containing Carob Extract on Carbohydrate Metabolism in Glucose-intolerant SubjectsNCT07420998 · 2026-01-26 · 1 site observation

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerNCT07225946 · 2025-12-19 · 1 site observation

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation

NOPE37: Angiogenic Factors for Managing Term PreeclampsiaNCT07193680 · 2025-12-04 · 1 site observation

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerNCT07173751 · 2025-10-30 · 2 site observations

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeNCT07284121 · 2025-07-15 · 2 site observations

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisNCT06315010 · 2025-06-27 · 1 site observation

Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.NCT07432191 · 2025-05-29 · 1 site observation

Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in SpainNCT06860945 · 2025-01-01 · 1 site observation

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05 · 1 site observation

Association of Assisted Reproductive Technologies Parameters With the Perinatal OutcomeNCT06918236 · 2024-10-01 · 1 site observation

Integrated Approach in Frail Older People with Atrial FibrillationNCT06775028 · 2024-04-11 · 2 site observations

A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer DetectionNCT06291896 · 2024-03-15 · 1 site observation

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure PatientsNCT06008197 · 2024-01-17 · 1 site observation

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · 2023-12-30 · 1 site observation

DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)NCT06055504 · 2023-09-06 · 1 site observation

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)NCT05898399 · 2023-06-30 · 1 site observation

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 2 site observations

MYTHS - MYocarditis THerapy With SteroidsNCT05150704 · 2021-10-07 · 1 site observation

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive PollenNCT04891237 · 2021-06-14 · 1 site observation

Efficacy and Safety Evaluation for the Treatment of Allergy Against MitesNCT04435990 · 2020-10-06 · 1 site observation

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM StudiesNCT03390894 · 2018-01-18 · 2 site observations

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)NCT02819882 · 2016-08-01 · 1 site observation

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS RegistryNCT02071134 · 2014-03-04 · 1 site observation

Optimizing the Use of Aspirin for the Prevention of PreeclampsiaNCT07665853 · 2026-07-01 · 1 site observation

NOT_YET_RECRUITING

Masitinib in Patients With Mild Alzheimer's DiseaseNCT05564169 · 2026-06-01 · 1 site observation

NOT_YET_RECRUITING

Effectiveness of Genistein in Mild Cognitive ImpairmentNCT07385937 · 2026-02-01 · 1 site observation

NOT_YET_RECRUITING

Preventive Nutritional Supplements for Preclinical PathologiesNCT07265115 · 2026-01-12 · 1 site observation

Innovative Functional Product for Overweight and ObesityNCT07044167 · 2025-09-07 · 1 site observation

Retrospective, Multicenter, Single-arm, Observational Study, With Data From Patients With T2DM With Malnutrition or at Risk, Who Were Prescribed Resource® Diabet Plus as a Hypercaloric and Hyperproteic Specific Formula for Patients With T2DMNCT06866366 · 2025-04-23 · 1 site observation

Acute Intervention with Sulforaphane-Smart®NCT06856486 · 2025-03-01 · 1 site observation

Clinical Trial to Evaluate the Effect of a Probiotic Product on WeightNCT06815926 · 2025-02-12 · 1 site observation

Effect of Psiguavin for Obesity Treatment (PSIGUAVIN)NCT06512818 · 2025-01-08 · 1 site observation

ENROLLING_BY_INVITATION

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)NCT06687369 · 2024-12-30 · 1 site observation

ACTIVE_NOT_RECRUITING

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.